Optimal use of maraviroc in clinical practice

AIDS. 2008 Nov 12;22(17):2231-40. doi: 10.1097/QAD.0b013e3283136d95.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active / adverse effects
  • CCR5 Receptor Antagonists
  • CD4 Lymphocyte Count / methods
  • Cyclohexanes / administration & dosage*
  • Drug Interactions
  • Drug Resistance, Viral
  • Female
  • HIV Fusion Inhibitors / administration & dosage*
  • HIV Infections / drug therapy*
  • HIV Infections / physiopathology
  • HIV-1* / isolation & purification
  • Humans
  • Male
  • Maraviroc
  • Receptors, CCR5 / isolation & purification*
  • Triazoles / administration & dosage*
  • Tropism / physiology
  • Viral Load

Substances

  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • HIV Fusion Inhibitors
  • Receptors, CCR5
  • Triazoles
  • Maraviroc